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Background: The existence of circulating tumor cells (CTCs) in patients with lung cancer has been reported. The
purpose of this study was to assess whether CTCs are predictive of the pathological effects of induction
chemoradiotherapy for patients with non-small cell lung cancer.
Methods: Patients who underwent induction chemoradiotherapy followed by surgery were compared with those
who underwent surgery alone. Peripheral and pulmonary venous blood samples from the involved lobe were
collected intraoperatively, and the number of CTCs was counted using the CellSearch™ system, an epithelial cell
adhesion molecule-based immunomagnetic technique.
Results: Of the 9 patients who underwent induction therapy, 4 achieved pathological CR, 4 achieved major response,
and 1 achieved minor response. All patients who underwent induction therapy and surgery alone were negative for
CTCs in peripheral blood. In the induction therapy group, 4 patients showing pathological CR were negative for CTCs in
pulmonary venous blood (pvCTCs) and 5 showing major/minor response were positive (mean, 57.8 cells). The numbers
of CTCs in patients showing major/minor response were significantly higher than those in patients showing
pathological CR (p = 0.012, Mann–Whitney U test). All 6 patients undergoing surgery alone were positive for pvCTCs
(mean, 207.5 cells), showing a significant difference from those undergoing induction therapy (p = 0.038).
Conclusions: The existence of CTCs in pulmonary venous blood reflects pathological non-CR, and therapeutic
pathological response may be predicted by pvCTC measurement.
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Primary lung cancer is the leading cause of cancer death in
most industrialized countries [1]. Although early stage
non-small cell lung cancer (NSCLC) is curable by surgical
resection [2-4], there is no established standard therapy for
resectable locally advanced NSCLC (e.g., bulky N2 disease)
[5]. Induction chemoradiotherapy followed by surgery for
locally advanced NSCLC remains controversial, but a fa-
vorable prognosis was reported in patients who achieved
pathological complete response (CR) [6]. At present, the
preoperative prediction of pathological response to induc-
tion therapy is inadequate, even with diagnostic imaging* Correspondence: starumi@med.kagawa-u.ac.jp
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reproduction in any medium, provided the ormodalities such as fluorine-18-fluorodeoxyglucose positron
emission tomography or computed tomography (CT) [7].
The concept of circulating tumor cells (CTCs) was de-
scribed by Paget in 1889 [8]. CTCs offer potential utility as
a prognostic, predictive, and/or pharmacodynamic bio-
marker [9-11], and CTC characterization is a research area
that could yield information on the mechanisms of metas-
tasis [12]. Previous studies demonstrated that CTCs can
be detected and quantitatively evaluated in patients with
primary lung cancer [10,13]. Although the detection rate
of CTCs was very low in the peripheral blood of lung can-
cer patients with no clinically detectable distant metastasis
[14-16], it was higher in pulmonary venous blood [17].
Since pathological CR is defined as a condition in which
no pathologically viable tumor cells remain [18], weLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Group IT (n = 9) Group SA (n = 6)
Age, median (range) 66 (57–75) 77 (63–90)
Gender Male Male
Histological cell type
Squamous cell carcinoma 6 1
Adenocarcinoma 3 4
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achieving CR, even in pulmonary venous blood. The
purpose of this study was to assess whether CTCs are
predictive of pathological response to induction che-
moradiotherapy. Therefore, we counted the number of
CTCs in pulmonary venous blood (pvCTCs) and per-
ipheral blood (periCTCs) and examined their relation-
ship with pathological response.
Methods
Patients
This study was conducted in Kagawa University Hospital
from December 2010 to January 2012. The institute re-
view boards of Kagawa University approved the study
protocol, and all patients provided written informed
consent. Patients agreeing to the purpose of the study
were eligible. All patients presented with a pathological
diagnosis of NSCLC and underwent an evaluation of sta-
ging by imaging studies, including contrast-enhanced
whole-body CT, contrast-enhanced magnetic resonance
brain imaging, and integrated positron emission tomog-
raphy/CT. Patients with concurrent or prior malignancy
treated within the previous 5 years were excluded.
Induction therapy and surgery
The details of induction chemoradiotherapy have been
described previously [6]. In brief, chemotherapy was
performed on weeks 1 and 5, and concurrent radiation
therapy with 50 Gy (2 Gy/day, 5 days/week) was
conducted from week 1 to week 5. The patients received
carboplatin (area under the curve 6 mg/[mL*min], 2-h
intravenous infusion) and docetaxel (60 mg/m2, 2-h
intravenous infusion) on day 1. Pulmonary resection
was performed by thoracotomy. All operations were
performed by one thoracic surgeon. As much as pos-
sible, pulmonary arteries were isolated and selected as





Complete response 4 -
Major response 4 -




Abbreviations: IT Induction chemoradiotherapy followed by surgery,
SA Surgery alone.
*Pathological stage means post-therapeutic stage (yp–stage) in the IT group.
**Lobectomy, including bilobectomy and lobectomy with bronchoplasty/
angioplasty.Estimation
The pathological effects of induction therapy were evalu-
ated according to the General Rules for Clinical and Patho-
logical Records of Lung Cancer, 7th edition [18]. Multiple
hematoxylin- and eosin-stained sections of each tumor
were reviewed by a pathologist and then re-reviewed by
another pathologist. After resectioning the entire tumor
and scrutinizing multiple cross-sections, this pathologist
carefully calculated the percentage of nonviable tumor
cells. The percentage of nonviable tumor cells was defined
as the combined percentage of scar and necrosis. Patho-
logical CR denotes that viable tumor cells do not exist in
the resected specimen; a major response denotes that vi-
able tumor cells remained in one-third of resected speci-
mens; a minor response denotes that viable tumor cellsremained in more than one-third of resected specimens;
and no response denotes that no pathological changes
were observed in the tumor cells of the resected specimen.
The pathologists were blinded to all clinical, radiological,
and surgical findings. Pathological diagnosis was defined
according to the pathologists’ comments on the clinical
records.
Peripheral and pulmonary venous blood samples
(7.5 mL each) from the lobe involved were collected
during thoracotomy for CTC enumeration. CTCs were
isolated from samples using the CellSearch™ system
(Veridex LLC, Raritan, NJ, USA), the technical details
of which, including accuracy, precision, linearity, and
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CTCs were defined as antibodies against epithelial cell
adhesion molecule (EpCAM)-isolated intact cells show-
ing positive staining for cytokeratin and negative stain-
ing for CD40. All CTCs were evaluated by two persons
having no knowledge of the clinical status of the pa-
tients. The finding of two or more CTCs was defined as
positive [13]. Correlation between the results of CTC
enumeration and pathological response was analyzed.
Data were compared using the Mann–Whitney U test.
The level of significance was set at 0.05. Statistical ana-
lysis of the data was performed using Statistical Package
for the Social Science for Windows, version 20.0.0 (IBM
SPSS , Chicago, IL, USA).Results
Patient characteristics are summarized in Table 1. Nine
patients underwent induction chemoradiotherapy and sur-
gery (IT group; all clinical stage 3A), and 6 underwent sur-
gery alone (SA group). Pathological CR and major and
minor responses were achieved in 4, 4, and 1 patients, re-
spectively. In the SA group, 2 patients each were at clinical
stages 1A and 1B and 1 patient each was at 2A and 2B.
CTC enumeration is shown in Table 2. All patients in both
groups were negative for periCTCs. Five patients in the IT
group were positive for pvCTCs (mean, 57.8 cells; range,
4–108). These patients showed major or minor response,
while the remaining 4 patients who achieved CR wereTable 2 CTC enumeration
Group Pt c-stage p-stage Pathological effec
IT #1 3A 0 Complete
IT #2 3A 0 Complete
IT #3 3A 0 Complete
IT #4 3A 0 Complete
IT #5 3A 1A Major
IT #6 3A 1B Major
IT #7 3A 3A Major
IT #8 3A 3A Major
IT #9 3A 3A Minor
SA #1 1A 1A -
SA #2 1A 1A -
SA #3 1B 1B -
SA #4 1B 1B -
SA #5 2A 2A -
SA #6 2B 2A -
Abbreviations: IT Induction chemoradiotherapy followed by surgery, SA Surgery alo
Pathological effect†; complete, viable tumor cells do not exist at all in the resected
specimens; minor, viable tumor cells remained in more than one-third of resected s
*Significant difference was observed between major/minor and complete response casesnegative for pvCTCs. A significant difference in the num-
bers of pvCTCs was observed between major/minor and
complete response cases (p = 0.012, Mann–Whitney U
test). All 6 patients in the SA group were positive for
pvCTCs (mean, 207.5 cells; range, 4–855), showing a sig-
nificant intergroup difference (p = 0.038).Discussion
The present study is the first to evaluate the relation-
ship between CTCs and the pathological effects of in-
duction chemoradiotherapy in NSCLC patients. CTC
count was found to be significantly higher in pulmonary
than in peripheral blood. In patients who underwent
induction chemoradiotherapy, pvCTC count was nega-
tive in the case of CR, whereas it was positive in the
other cases.
While patients who achieved pathological CR by induc-
tion chemoradiotherapy plus surgery achieved favorable
prognosis [5], it is difficult to evaluate pathological CR fol-
lowing induction therapy. If it is possible to confirm CR
patients before operation, patient selection based on surgi-
cal indications will be possible and may contribute to a
prognostic improvement. Usage of pvCTCs has the poten-
tial to accurately reflect the pathological effects of induc-
tion therapy, and their measurement is useful in the
prediction of pathological CR. This suggests that it would
be possible to conduct a prospective study of patients
achieving pathological CR by induction chemoradiotherapy.t† periCTCs pvCTCs*
Evaluation Count Evaluation Count
Negative 0 Negative 0
Negative 0 Negative 0
Negative 1 Negative 0
Negative 0 Negative 1
Negative 0 Positive 12
Negative 0 Positive 60
Negative 0 Positive 4
Negative 0 Positive 5
Negative 0 Positive 108
Negative 0 Positive 4
Negative 0 Positive 51
Negative 0 Positive 8
Negative 0 Positive 216
Negative 0 Positive 111
Negative 0 Positive 855
ne.
specimen; major, viable tumor cells remained in one-third of resected
pecimens.
(p = 0.012, Mann–Whitney U test) and between the SA and IT groups (p = 0.038).
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in patients achieving CR may then be easier to answer, be-
cause preoperative evaluation would be possible when a
pulmonary vein catheter technique (e.g., pulmonary vein
isolation) is used [19].
In the IT group, the number of patients with squamous
cell carcinoma was greater than that of patients with
adenocarcinoma. Three patients with squamous cell car-
cinoma were positive for pvCTCs and 3 were negative.
Two and 1 patient with adenocarcinoma were positive
and negative for pvCTCs, respectively. Okumura and
colleagues reported that the incidence of positive
periCTCs was significantly higher in squamous cell car-
cinoma than in adenocarcinoma, but no correlation was
observed between pvCTC count and histological type
[17]. To investigate the correlation between pvCTC
count and histological type, futher study is required.
The cause for the difference in the number of pvCTCs
and periCTCs remains unclear. As for the result, the
role of destruction within the blood stream or seeding
to tissue bed is considered as a hypothesis.
The major limitation of this study is that the study
population was small, and greater patient numbers are
desirable for further study. Further study using a large
sample size is important for making definitive conclu-
sions. Sawabata and colleagues reported that periCTCs
were detected in NSCLC cases following surgical ma-
nipulation [20]. That study also raised concerns over the
use of pvCTCs. However, since periCTCs and pvCTCs
(in cases showing CR) obtained intraoperatively were all
negative, this concern may be ruled out.
In CTC detection, clustered cells were hardly ex-
tracted from the blood using the CellSearch™ system.
EpCAM-based enrichment methods such as use of the
CellSearch™ system have a limitation in that EpCAM
can be downregulated during epithelial–mesenchymal
transition [21]. A recent study indicated that this pro-
cess is attributable to metastasis [22]. Various alternate
methods are currently available [23-27], and it may be
necessary to verify results using other methods.
The present study has established a new role for CTC
analysis in the evaluation of induction chemoradiotherapy.
While sampling of pulmonary venous blood is currently
not easy, the development of a new, non-invasive proced-
ure for sampling pulmonary venous blood would enable
determination of pathological CR preoperatively. We
may be able to verify the likely efficacy of surgery after in-
duction chemoradiotherapy in the treatment of locally
advanced NSCLC.Conclusions
No pvCTCs were found in the group showing pathological
CR. Although the sample size was limited, a significantdifference was observed in the numbers of pvCTCs be-
tween the CR and non-CR groups. In addition, all patients
who did not receive induction chemoradiotherapy were
positive for pvCTCs regardless of disease stage. The
pvCTC status accurately reflected pathological CR in this
study, and pathological response may therefore be predict-
able through pvCTC measurement.
Abbreviations
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